First entirely AI developed drug green lit for clinical trial

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Exscientia, AI, Drug discovery, Sumitomo Dainippon Pharma

A drug candidate for obsessive-compulsive disorder will enter clinical trials, after being discovered and readied in under 12 months.

This rapid turnaround from discovery to clinical trial is part of the reason that industry is excited about the potential for artificial intelligence​. Usually, the drug development pathway averages four and a half years to get to the same stage, noted one of the companies involved, Exscientia.

The drug is DSP-1181, which is a long-acting and potent serotonin 5-HT1A​ receptor agonist, which will enter Phase I trials in Japan for obsessive-compulsive disorder.

The drug candidate was created through the joint research of Japanese pharma company Sumitomo Dainippon Pharma and Exscientia, with the latter providing the Centaur Chemist AI platform for discovery.

Andrew Hopkins, CEO of Exscientia, stated: "We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.”

While the company’s Twitter account​ suggested that it expects all drugs by the end of the decade to be developed using AI.

Several pharma companies have expressed their own confidence in this prospect, with both Sanofi​ and, more recently, Bayer​ entering multi-million drug development deals with the AI specialist.

Related news

Show more

Related products

show more

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us

Products

View more

Webinars